Ranking adverse drug reactions with crowdsourcing

Journal of Medical Internet Research

Volumn 17, Issue 3, 2015, Pages

  Gottlieb, Assaf ^a   Hoehndorf, Robert ^b   Dumontier, Michel ^c   Altman, Russ B ^a  

^a STANFORD UNIVERSITY   (United States)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug reactions; Alert fatigue; Crowdsourcing; Drug side effects; Patient centered care; Pharmacovigilance

Indexed keywords

ADULT; ADVERSE DRUG REACTION; CROWDSOURCING; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INTERNET; MALE; PATIENT CARE; PROCEDURES; RISK ASSESSMENT; STANDARDS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CROWDSOURCING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INTERNET; MALE; PATIENT-CENTERED CARE; PHARMACOVIGILANCE; RISK ASSESSMENT;

EID: 84929664404     PISSN: None     EISSN: 14388871     Source Type: Journal    
DOI: 10.2196/jmir.3962     Document Type: Article

References (29)

1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995 Jul 5;274(1):29-34. [Medline: 7791255]
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277(4):301-306. [Medline: 9002492]
3. Shaffer ML, Watterberg KL. Joint distribution approaches to simultaneously quantifying benefit and risk. BMC Med Res Methodol 2006;6:48 [FREE Full text] [doi: 10.1186/1471-2288-6-48] [Medline: 17038184]
4. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health 2010 Aug;13(5):657-666. [doi: 10.1111/j.1524-4733.2010.00725.x] [Medline: 20412543]
5. Holden WL, Juhaeri J, Dai W. Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiol Drug Saf 2003 Dec;12(8):693-697. [doi: 10.1002/pds.794] [Medline: 14762986]
6. Tallarida R, Murray RB, Eiben C. A scale for assessing the severity of diseases and adverse drug reactions. Application to drug benefit and risk. Clin Pharmacol Ther 1979 Apr;25(4):381-390. [Medline: 428184]
7. Tallarida RJ, Smith TM, Johnson AF, Blodgett RC. Non-physicians and physicians assess severity of disease states and adverse drug reactions : Application to drug benefit-risk measurement. Pharmaceutical Medicine 1984;1(1):41-46.
8. Buhrmester M, Kwang T, Gosling SD. Amazon's Mechanical Turk: A new source of inexpensive, yet high-quality, data? Perspectives on Psychological Science 2011 Feb 03;6(1):3-5. [doi: 10.1177/1745691610393980]
9. Atias N, Sharan R. An algorithmic framework for predicting side effects of drugs. J Comput Biol 2011 Mar;18(3):207-218. [doi: 10.1089/cmb.2010.0255] [Medline: 21385029]
10. Huang L, Wu X, Chen JY. Predicting adverse side effects of drugs. BMC Genomics 2011 Dec 23;12 Suppl 5:S11 [FREE Full text] [doi: 10.1186/1471-2164-12-S5-S11] [Medline: 22369493]
11. Gottlieb A, Altman RB. Integrating systems biology sources illuminates drug action. Clin Pharmacol Ther 2014 Jun;95(6):663-669. [doi: 10.1038/clpt.2014.51] [Medline: 24577151]
12. Kesselheim AS, Cresswell K, Phansalkar S, Bates DW, Sheikh A. Clinical decision support systems could be modified to reduce 'alert fatigue' while still minimizing the risk of litigation. Health Aff (Millwood) 2011 Dec;30(12):2310-2317 [FREE Full text] [doi: 10.1377/hlthaff.2010.1111] [Medline: 22147858]
13. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343 [FREE Full text] [doi: 10.1038/msb.2009.98] [Medline: 20087340]
14. Tatonetti N, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med 2012 Mar 14;4(125):125ra31 [FREE Full text] [doi: 10.1126/scitranslmed.3003377] [Medline: 22422992]
15. Kuhn M, Al BM, Campillos M, Jensen LJ, Gross C, Gavin AC, et al. Systematic identification of proteins that elicit drug side effects. Mol Syst Biol 2013;9:663 [FREE Full text] [doi: 10.1038/msb.2013.10] [Medline: 23632385]
16. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999 Feb;20(2):109-117. [Medline: 10082069]
17. The Adverse Event Reporting System (AERS): Older Quarterly Data Files. 2014. URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm083765.htm [accessed 2014-10-21] [WebCite Cache ID 6TUzsQGjw]
18. Brooks M. Medscape. 2014 Jan 30. Top 100 selling drugs of 2013 URL: http://www.medscape.com/viewarticle/820011 [accessed 2014-10-21] [WebCite Cache ID 6TV0IQ419]
19. Köhler S, Doelken SC, Mungall CJ, Bauer S, Firth HV, Bailleul-Forestier I, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res 2014 Jan;42(Database issue):D966-D974 [FREE Full text] [doi: 10.1093/nar/gkt1026] [Medline: 24217912]
20. Harispe S, Ranwez S, Janaqi S, Montmain J. The semantic measures library and toolkit: fast computation of semantic similarity and relatedness using biomedical ontologies. Bioinformatics 2014 Mar 1;30(5):740-742 [FREE Full text] [doi: 10.1093/bioinformatics/btt581] [Medline: 24108186]
21. IBM Corp. 2010. IBM ILOG AMPL Version 12.2 User's Guide URL: http://ampl.com/BOOKLETS/amplcplex122userguide.pdf [accessed 2015-03-11] [WebCite Cache ID 6Wwyajqyy]
22. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society. Series B (Methodological) 1996;58(1):267-288 [FREE Full text] [WebCite Cache]
23. Rubio C, Hill ME, Milan S, O'Brien ME, Cunningham D. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997;75(7):1044-1048 [FREE Full text] [Medline: 9083341]
24. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997 Jan;40(1):141-151. [Medline: 8971836]
25. Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007 May 30;27(22):5903-5914 [FREE Full text] [doi: 10.1523/JNEUROSCI.5270-06.2007] [Medline: 17537961]
26. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008;28(1):97-106. [doi: 10.1159/000109398] [Medline: 17914251]
27. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K. Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 2005 Nov;128(Pt 11):2675-2688 [FREE Full text] [doi: 10.1093/brain/awh627] [Medline: 16219674]
28. Zhao F, Li P, Chen SR, Louis CF, Fruen BR. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001 Apr 27;276(17):13810-13816 [FREE Full text] [doi: 10.1074/jbc.M006104200] [Medline: 11278295]
29. Phansalkar S, van der Sijs H, Tucker AD, Desai AA, Bell DS, Teich JM, et al. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J Am Med Inform Assoc 2013 May 1;20(3):489-493 [FREE Full text] [doi: 10.1136/amiajnl-2012-001089] [Medline: 23011124]